[vc_row][vc_column][vc_column_text][/vc_column_text][mk_blog style=”thumbnail” image_size=”full” post_count=”20″ pagination_style=”3″ image_quality=”1″ count=”20″ offset=”0″ disable_lightbox=”false” disable_comments_share=”true” item_id=”1451373577-56823409066c3″ cat=”1544, 1534, 1552, 1536, 1532, 1554, 1539″ exclude_post_format=””][/vc_column][/vc_row]
In Europe, 2024 marks the year when exclusivity for a diverse range of drugs encompassing various therapeutic categories is set to expire. This includes established medications like Cabometyx and Zavicefta
During the second quarter of 2023, there was a 7% increase in patent applications for immuno-oncology compared to the previous quarter, indicating a dynamic transformation in the oncology landscape. Interestingly,
As a researcher, What is one of the biggest challenges faced by you in your organization? We asked this question both internally and to some of our clients and here’s
Investment decisions are not made in a vacuum, they have a context. The main question is – What is that context which you should set, as an investor or a
“More than 75% of SEP litigations involve 3GPP standards, including these days’ hot topic i.e., 5G standard and its predecessor i.e., 4G, 3G, and 2G.” – IPWatchdog The stakes in
